Utility, Safety, and Effectiveness of the Bard LifeStent 5F Vascular Stent System

Inclusion criteria

• The subject or legal representative has been informed of the nature of the evaluation, agrees to its provisions, and has signed the informed consent form (ICF).
• Subject agrees to comply with the protocol-mandated follow-up procedures and visits.
• The subject is ≥ 21 years of age.
• The subject has lifestyle-limiting claudication to mild tissue loss defined as: Rutherford Category 2-5 (moderate claudication to minor tissue loss).
• The target lesion(s) has angiographic evidence of a hemodynamically relevant stenosis or restenosis ≥50% or occlusion of the SFA and/or popliteal artery (by visual estimate) and is amenable to PTA and stenting.
• The target vessel reference diameter will be (by visual estimate) appropriate for treatment with available stent diameters of 5.0, 6.0 and 7.0 mm.
• A total of two stents may be used to treat a target lesion. Overlapping is allowed.
• There is angiographic evidence of at least one vessel runoff to the foot (at the level of the malleolus).

Exclusion criteria

• The subject is unable or unwilling to provide informed consent or is unable or unwilling to comply with the study follow-up procedure and visits.
• The subject has claudication or critical limb ischemia described as Rutherford Category 0 (asymptomatic), 1 (mild claudication), or 6 (major tissue loss).
• The subject has a known contraindication (including allergic reaction) or sensitivity to nickel, titanium or tantalum.
• The subject has a known allergy of hypersensitivity to contrast media which cannot be adequately pre-medicated.
• The subject has a known uncontrolled blood coagulation/bleeding disorder.
• The subject has concomitant renal failure with a creatinine of >2.5 mg/dL.
• The subject has concomitant hepatic insufficiency, thrombophlebitis, uremia, systemic lupus erythematosus (SLE), or deep vein thrombosis (DVT) at the time of the study procedure.
• The subject is receiving dialysis or immunosuppressive therapy.
• The subject is diagnosed with septicemia at the time of the study procedure.
• The subject is participating in an investigational drug or another investigational device study.
• The subject has another medical condition, which, in the opinion of the investigator, may cause him/her to be noncompliant with the protocol, confound the data interpretation, or is associated with limited life expectancy not sufficient to complete all study procedures.
• The subject has extensive peripheral vascular disease, which, in the opinion of the investigator, precludes safe insertion of an introducer sheath.
• The target lesion is located within an aneurysm or associated with an aneurysm in the vessel segment either proximal or distal to the target lesion.
• The subject has angiographic evidence of poor inflow, which would be deemed inadequate to support a vascular bypass graft.
• The subject has severe calcification of the target lesion, which prevents inflation of a PTA balloon (pre-dilatation of the target lesion is required).
• The subject has angiographic evidence of large acute thrombus at the target lesion.
• Subjects with a stent previously implanted into the target lesion. A target vessel with a previously placed stent is permitted as long as the subject device(s) will not come into contact with the previously placed stent during treatment of the target lesion.
• Lesion requiring the use of more than two stents.
• Bilateral disease in the native SFA and/or popliteal artery where both limbs meet the inclusion/exclusion criteria and it is planned to treat both limbs within 30 days. Note: One limb may be enrolled in the study, but only if the second limb is planned to be treated after the 30 day follow-up telephone screening has taken place. The limb that may be enrolled has to be the limb with the more severe lesion and the reasons for treating this specific limb will need to be stated in the case report form (CRF).
• The subject had a prior vascular intervention within 30 days before, or has an intervention planned for within 30 days after the index procedure. Note: Additional non-target lesions may be treated during the index procedure.